Feb 25, 2013, 10.00 AM IST
HSBC raised its rating on shares of Ranbaxy Laboratories Ltd to 'overweight' from 'underweight' after the Indian drugmaker said it would resume production of a generic version of cholesterol fighter Lipitor for sale in the United States.
HSBC added other factors behind its upgrade were share valuations after a recent correction, as well as the near-term catalysts such as the launch of additional generic drugs and the probability of a recovery in US sales.
Ranbaxy Labs' shares were up 4.22 percent to Rs 430.75 as of 9:58 am.
Ranbaxy Labs stock price
On December 10, 2013, at 10:06 hrs Ranbaxy Laboratories was quoting at Rs 436.45, up Rs 2.45, or 0.56 percent. The 52-week high of the share was Rs 525.00 and the 52-week low was Rs 253.95.
The latest book value of the company is Rs 45.40 per share. At current value, the price-to-book value of the company was 9.61.
Action in Ranbaxy Laboratories
Video of the day
Dec 6 2013, 15:02
- in MARKET OUTLOOK
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.